Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-116708
Filing Date
2024-10-23
Accepted
2024-10-23 17:00:19
Documents
55
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vktx-20240930.htm   iXBRL 10-Q 2049566
2 EX-31.1 vktx-ex31_1.htm EX-31.1 16549
3 EX-31.2 vktx-ex31_2.htm EX-31.2 16525
4 EX-32.1 vktx-ex32_1.htm EX-32.1 12164
  Complete submission text file 0000950170-24-116708.txt   8092474

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vktx-20240930.xsd EX-101.SCH 1063215
57 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20240930_htm.xml XML 1406958
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37355 | Film No.: 241389720
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)